Helus Pharma (HELP) Heads To Guggenheim Conference, Is The 78% Undervalued View Credible?
Helus Pharma (NasdaqGM:HELP) is back on investor calendars after confirming a slot at the 3rd Annual Guggenheim Healthcare Innovation Conference in Boston on November 9, featuring CEO Michael I. Halstead.
Recent trading tells a mixed story. Helus Pharma’s share price is US$9.07 after a 1 day decline of 3.2% and a 30 day fall of 23.1%. However, the year to date share price return is 9.5% and the 1 year total shareholder return is 42.8%, which points to longer term momentum despite short term pressure around events like this conference appearance.
Scan for other mental health and biotech stories potentially setting up similar moves by checking the 36 healthcare AI stocks alongside Helus Pharma ahead of this conference appearance.
Helus Pharma now trades far below both analyst targets and some intrinsic value estimates after that sharp 30 day slide. Is this simply caution around losses and clinical risk, or has pricing swung too far?
Most Popular Narrative: 78% Undervalued
On the analyst consensus Narrative on Simply Wall St, Helus Pharma’s fair value sits at $41.62 per share compared with the latest close at $9.07, which frames a wide gap that the market is still debating ahead of the Boston conference.
The analysts have a consensus price target of $41.62 for Cybin based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $70.49, and the most bearish reporting a price target of just $15.37.
See why 19 investors see Helus Pharma as 78% undervalued.
Result: Fair Value of $41.62 (UNDERVALUED)
Still, Helus Pharma’s reliance on successful HLP003 and HLP004 trial outcomes, along with continued losses of US$171.2 million, could quickly challenge that undervalued narrative.
Find out about the key risks to this Helus Pharma narrative.
Another View: Helus Pharma On Book Value
Fair value models paint Helus Pharma as heavily undervalued, yet the simple P/B snapshot tells a more cautious story. HELP trades on a 2.7x P/B, richer than the US Pharmaceuticals average of 1.9x but below the 3.4x peer level. This raises the question of whether that gap signals risk or room for repricing.
To see how this price tag stacks up against other valuation checks from the same toolkit, and how much of that premium the market might be willing to support over time, take a closer look at our breakdown: See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around Helus Pharma is pulled in two directions, with clear concerns and clear hopes. Move quickly, review the data and weigh the 2 key rewards and 5 important warning signs.
Looking for more ideas beyond Helus Pharma?
If Helus Pharma has your attention, consider broadening the watchlist with a few fresh angles that could surface different risk and reward profiles.
- Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations through the 36 high quality undervalued stocks.
- Prioritise resilience by reviewing a list of solid balance sheet and fundamentals (24 results) that can help you stress test your portfolio against tougher conditions.
- Get ahead of the crowd by surveying 20 high quality undiscovered gems that most investors may not be watching yet.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com